Incyte Corp Ltd (INCY): Today's Featured Health Care Winner

Incyte ( INCY) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day down 0.1%. By the end of trading, Incyte rose 17 cents (0.7%) to $25.32 on light volume. Throughout the day, 954,165 shares of Incyte exchanged hands as compared to its average daily volume of 1.8 million shares. The stock ranged in a price between $24.80-$25.41 after having opened the day at $24.98 as compared to the previous trading day's close of $25.15. Other companies within the Health Care sector that increased today were: Sunshine Heart ( SSH), up 65.8%, Chelsea Therapeutics International ( CHTP), up 41.5%, Palatin Technologies ( PTN), up 27.9%, and Escalon Medical Corporation ( ESMC), up 26.1%.

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary small molecule drugs for oncology and inflammation. Incyte has a market cap of $3.16 billion and is part of the drugs industry. Shares are up 67.6% year to date as of the close of trading on Thursday. Currently there are 13 analysts that rate Incyte a buy, no analysts rate it a sell, and three rate it a hold.

TheStreet Ratings rates Incyte as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, weak operating cash flow and feeble growth in its earnings per share.

On the negative front, Sucampo Pharmaceuticals Inc. A ( SCMP), down 24.8%, K-V Pharmaceutical Company ( KV.A), down 23.1%, K-V Pharmaceutical Company ( KV.B), down 12.6%, and American Caresource Holdings ( ANCI), down 11.4%, were all losers within the health care sector with Vertex Pharmaceuticals ( VRTX) being today's health care sector loser.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).
null

If you liked this article you might like

Clovis Spikes on Phase 3 Data for Ovarian Cancer Drug- Biotech Movers

Cramer: There Should Be More Takeovers Where These Came From

Otonomy Shares Fall On Disappointing Phase 3 Data - Biotech Movers

Eli Lilly Shares Lower After Update on Rheumatoid Arthritis Drug

How Competition Drives Stocks Nowhere: Cramer's 'Mad Money' Recap (Tuesday 7/11/17)